vs
Beam Therapeutics Inc.（BEAM）与ORRSTOWN FINANCIAL SERVICES INC（ORRF）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是ORRSTOWN FINANCIAL SERVICES INC的1.8倍（$114.1M vs $64.6M），Beam Therapeutics Inc.净利率更高（214.1% vs 33.8%，领先180.3%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
奥尔斯敦金融服务公司是总部位于美国宾夕法尼亚州的区域性银行控股企业，提供零售及商业银行服务，涵盖存款账户、个人与企业贷款、按揭产品、财富管理等业务，主要服务宾州中部及马里兰州北部的个人客户和中小微企业。
BEAM vs ORRF — 直观对比
营收规模更大
BEAM
是对方的1.8倍
$64.6M
净利率更高
BEAM
高出180.3%
33.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $64.6M |
| 净利润 | $244.3M | $21.8M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | — |
| 净利率 | 214.1% | 33.8% |
| 营收同比 | 279.5% | — |
| 净利润同比 | 370.4% | 19.1% |
| 每股收益（稀释后） | $2.53 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMORRF
| Q1 26 | — | $64.6M | ||
| Q4 25 | $114.1M | $64.9M | ||
| Q3 25 | — | $64.4M | ||
| Q2 25 | — | $62.4M | ||
| Q1 25 | — | $60.4M | ||
| Q4 24 | — | $61.8M | ||
| Q3 24 | — | $64.1M | ||
| Q2 24 | — | $33.3M |
净利润BEAMORRF
| Q1 26 | — | $21.8M | ||
| Q4 25 | $244.3M | $21.5M | ||
| Q3 25 | — | $21.9M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $18.1M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $-7.9M | ||
| Q2 24 | — | $7.7M |
营业利润率BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | -15.3% | 42.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 39.6% | ||
| Q1 25 | — | 37.7% | ||
| Q4 24 | — | 27.7% | ||
| Q3 24 | — | -15.4% | ||
| Q2 24 | — | 29.5% |
净利率BEAMORRF
| Q1 26 | — | 33.8% | ||
| Q4 25 | 214.1% | 33.1% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 31.2% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | — | -12.3% | ||
| Q2 24 | — | 23.3% |
每股收益（稀释后）BEAMORRF
| Q1 26 | — | $1.12 | ||
| Q4 25 | $2.53 | $1.11 | ||
| Q3 25 | — | $1.13 | ||
| Q2 25 | — | $1.01 | ||
| Q1 25 | — | $0.93 | ||
| Q4 24 | — | $0.35 | ||
| Q3 24 | — | $-0.41 | ||
| Q2 24 | — | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $161.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $603.2M |
| 总资产 | $1.5B | $5.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMORRF
| Q1 26 | — | $161.8M | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BEAMORRF
| Q1 26 | — | $603.2M | ||
| Q4 25 | $1.2B | $591.5M | ||
| Q3 25 | — | $571.9M | ||
| Q2 25 | — | $548.4M | ||
| Q1 25 | — | $532.9M | ||
| Q4 24 | — | $516.7M | ||
| Q3 24 | — | $516.2M | ||
| Q2 24 | — | $278.4M |
总资产BEAMORRF
| Q1 26 | — | $5.6B | ||
| Q4 25 | $1.5B | $5.5B | ||
| Q3 25 | — | $5.5B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $5.5B | ||
| Q2 24 | — | $3.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | $-83.3M | $74.7M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | — | $24.5M | ||
| Q1 25 | — | $11.0M | ||
| Q4 24 | — | $35.0M | ||
| Q3 24 | — | $7.5M | ||
| Q2 24 | — | $6.4M |
自由现金流BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $70.5M | ||
| Q3 25 | — | $22.3M | ||
| Q2 25 | — | $23.7M | ||
| Q1 25 | — | $8.6M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $6.4M |
自由现金流率BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | 108.6% | ||
| Q3 25 | — | 34.7% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 11.1% | ||
| Q2 24 | — | 19.2% |
资本支出强度BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 6.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.1% |
现金转化率BEAMORRF
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | 3.48× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.26× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | — | 2.55× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
ORRF
| Net Interest Income | $49.0M | 76% |
| Noninterest Income | $15.6M | 24% |
